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Purpose: In an earlier study we found normal adeno-associated viral vector type 2 (AAV2)-mediated GFP expression
after intravitreal injection to one eye of normal C57BL/6J mice. However, GFP expression was very poor in the partner
eye of the same mouse if this eye received an intravitreal injection of the same vector one month after the initial intravitreal
injection. We also found both injections worked well if they were subretinal. In this study, we tested whether the efficiency
of subretinal AAV vector transduction is altered by a previous intravitreal injection in the partner eye and more importantly
whether therapeutic efficiency is altered in the rd12 mouse (with a recessive RPE65 mutation) after the same injection
series.
Methods: One μl of scAAV5-smCBA-GFP (1x1013 genome containing viral particles per ml) was intravitreally injected
into the right eyes of four-week-old C57BL/6J mice and 1 μl of scAAV5-smCBA-hRPE65 (1x1013 genome containing
viral particles per ml) was intravitreally injected into the right eyes of four-week-old rd12 mice Four weeks later, the same
vectors were subretinally injected into the left eyes of the same C57BL/6J and rd12 mice. Left eyes of another cohort of
eight-week-old rd12 mice received a single subretinal injection of the same scAAV5-smCBA-hRPE65 vector as the
positive control. Dark-adapted electroretinograms (ERGs) were recorded five months after the subretinal injections. AAV-
mediated GFP expression in C57BL/6J mice and RPE65 expression and ERG restoration in rd12 mice were evaluated
five months after the second subretinal injection. Frozen section analysis was performed for GFP fluorescence in C57BL/
6J mice and immunostaining for RPE65 in rd12 eyes.
Results: In rd12 mice, dark-adapted ERGs were minimal following the first intravitreal injection of scAAV5-smCBA-
RPE65. Following subsequent subretinal injection in the partner eye, dramatic ERG restoration was recorded in that eye.
In fact, ERG b-wave amplitudes were statistically similar to those from the eyes that received the initial subretinal injection
at a similar age. In C57BL/6J mice, GFP positive cells were detected in eyes following the first intravitreal injection
around the injection site. Strong GFP expression in both the retinal pigment epithelium (RPE) and photoreceptor (PR)
cells was detected in the partner eyes following the subsequent subretinal injection. Immunostaining of retinal sections
with anti-RPE65 antibody showed strong RPE65 expression mainly in the RPE cells of subretinally injected eyes but not
in the intravitreally injected eyes except minimally around the injection site.
Conclusions: These results show that an initial intravitreal injection of AAV vectors to one eye of a mouse does not
influence AAV-mediated gene expression or related therapeutic effects in the other eye when vectors are administered to
the subretinal space. This suggests that the subretinal space possesses a unique immune privilege relative to the vitreous
cavity.
Immune privilege is one of the important features of the
eye, which makes it an attractive target for gene therapy. The
posterior part of the eye also appears to have immune deviant
features. Streilein et al. [1–4] reported an immune-deviant
response  against  soluble  and  cell-bound  antigens  in  the
subretinal space. The anatomic structure of the eye may assist
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in mediating immune deviation including the fact that much
of the eye is avascular. In addition, there are several cellular
and physical barriers, which enforce the separation from the
blood supply.
Adeno-associated virus (AAV) is a human parvovirus,
which has not been associated with human disease [5]. It has
favorable  immunologic  characteristics  as  a  vector  after
deleting all viral open reading frames and retaining only the
inverted terminal repeat sequences (ITRs) [6]. Exposure to
recombinant AAV has not been reported to induce a cell-
mediated immune response in the eye. However, this virus can
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267induce a strong antibody response directed at both viral capsid
antigens and the transgene [7–9]. Antibodies are detected in
the intraocular fluid (anterior chamber fluid and vitreous) as
well as in the serum.
Although both the vitreous cavity (VC) and subretinal
(SR) spaces possess immune privilege, the VC space behaves
differently to AAV-mediated gene transfer than the SR space
[10]. The VC space is capable of eliciting an immune response
against AAV capsid while the SR space is not. The precise
mechanism remains unknown. However, it is possible that the
VC outflow mechanisms and its close proximity to vascular
systems play critical roles in the immune response. The SR
space  is  a  potential  space  between  the  retinal  pigment
epithelium  (RPE)  and  photoreceptor  (PR)  cells.  The  RPE
monolayer  forms  the  outer  blood-retina  barrier  (BRB),
separating the choroicapillaris from the neural retina, and
controls the exchange of molecules between the retina and
choroid [10]. RPE cells can also secrete different immune-
suppressive and anti-inflammatory molecules as well as cell
membrane-bound molecules, which can induce apoptosis of
inflammatory cells and contribute to ocular immune privilege
[11–14].
Studies of repeated administration of AAV vectors into
non-ocular tissue indicate that immune responses generated
after the first administration may prevent further application
[15–20]. While it is generally assumed that pre-exposure to
AAV will not pose significant problems for the efficacy of
AAV vectors in the retina, an immune privileged site, no study
had been carried to examine the impact of previous intravitreal
injection in one eye on subsequent AAV vector-mediated
therapy  in  the  second  eye.  Recently,  we  found  that  an
intravitreal  injection  of  AAV2-CBA-pigment  epithelium-
derived factor (PEDF) into C57-BL/6J mice resulted in a
humoral  immune  response  against  AAV2  capsid,  which
prevented therapy when the same vector was re-administrated
to the VC of the contralateral eye [10]. In a parallel study, we
found  normal  AAV2-mediated  GFP  expression  after  an
intravitreal injection to one eye of normal C57BL/6J mice. In
contrast, GFP expression was very poor in the other eye of the
same mouse if it received a subsequent intravitreal injection
of the same vector one month after the initial intravitreal
injection in the partner eye. However, both injections worked
well if they were subretinal [10].
Since  the  Leber  congenital  amaurosis  (LCA2,  with
RPE65 mutation) clinical trial began and only one eye was
treated each time [21–24], this raises the concern that an initial
subretinal injection may affect the future therapeutic effect of
later treatments in the contralateral eye of that patient. This
concern stems from the possible chance that some AAV vector
might leak into the vitreous cavity during or after the original
subretinal injection procedure.
Recently, a naturally occurring mouse model of human
LCA with RPE65 mutations, the rd12 mouse, was reported
[25]. In this model, a recessive nonsense mutation in Rpe65
leads to the absence of the RPE65 protein and blockage of the
retinoid cycle, which is essential for rod function. Because of
undetectable levels of RPE65, 11-cis-retinal, and rhodopsin
at any age, no normal, dark-adapted electroretinogram (ERG)
was detected in rd12 mice and slow rod degeneration ensued
[25].  RPE65,  11-cis  retinal,  and  rod  ERGs  were  restored
following  subretinal  delivery  of  either  AAV2-RPE65  or
AAV5-RPE65 at different ages of RPE65 deficient mice [26–
29].
In this study, we used the rd12 mouse to test whether the
efficiency of subretinal AAV-RPE65 therapy is altered by a
previous intravitreal treatment of the partner eye with the same
vector  and  whether  we  can  restore  ERG  function  in  the
subretinally treated rd12 eye.
METHODS
Animals: C57BL/6J mice and the congenic inbred strain of
rd12 mice were obtained from the Jackson Laboratory (Bar
Harbor,  ME)  and  bred  at  Wenzhou  Medical  College
(Wenzhou, China). All mice were maintained in the Animal
Facilities of Wenzhou Medical College under a 12-h light/12-
h  dark  cycle.  Sixty  mice  were  used  in  this  study.  All
experiments  were  approved  by  the  Wenzhou  Medical
College’s Institutional Animal Care and Use Committee and
were conducted in accordance with the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research.
Adeno-associated virus type 5 vector preparation: The vector
plasmid of self-complementary (sc) human RPE65 (hRPE65)
with a small, hybrid cytomegalovirus (CMV)-chicken β-actin
(smCBA) promoter (sc-smCBA-hRPE65) was constructed by
replacing  the  humanized  green  fluorescent  protein  (GFP)
cDNA of sc-smCBA-hGFP with the human RPE65 cDNA via
flanking Not I sites. The vector plasmid for scAAV5-smCBA-
hRPE65 was constructed by replacing the humanized GFP
cDNA of sc-smCBA-hGFP with the human RPE65 cDNA,
via a Not I digest. Both constructs contain flanking AAV
serotype  2  inverted  terminal  repeats  (ITR);  one  ITR  has
modifications required for packaging as a self complementary
AAV  vector  [30].  Pseudotyped  AAV5  capsid,  self-
complementary AAV5 vectors (scAAV5) were used in this
study as they have been shown to be more efficient vectors
for transduction of the retina than standard, single-stranded
AAV  vectors  [31,32].  The  therapeutic  vector  (scAAV5-
smCBA-hRPE65)  has  been  shown  to  have  identical
transduction and tropism characteristics as the full chimeric
CMV-CBA promoter when targeted to the mouse retina [33].
Vectors were manufactured by previously described methods
[34]. Viral preparations had an average titer of 1013 genome-
containing  viral  particles  per  ml.  The  vector  titer  was
determined by real time polymerase chain reaction (PCR), and
final  aliquots  were  resuspended  in  balanced  salt  solution
(Alcon  Laboratories,  Forth  Worth  TX)  with  0.014%
Tween-20 (J.T. Baker, Inc., Phillipsburg, NJ).
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268Subretinal and intravitreal injections: One μl of scAAV5-
smCBA-GFP (1x1013 genome containing viral particles per
ml) was intravitreally injected into the right eyes of four-
week-old  C57BL/6J  mice  and  1  μl  of  scAAV5-smCBA-
hRPE65 (1x1013 genome containing viral particles per ml) was
intravitreally injected into the right eyes of four-week-old
rd12  mice.  Four  weeks  later  the  same  vectors  were
subretinally injected into the left eyes of the same C57BL/6J
or rd12 mice using a previously described method [26]. Ten
eight-week-old  rd12  mice  received  a  single  subretinal
injection to their right eyes with the same scAAV5-smCBA-
hRPE65 vector as the positive control.
For subretinal injections, 1 μl vector suspension with 1%
fluorescein, diluted from 25% AK-FLUR (Akorn, Buffalo
Grove,  IL)  was  slowly  injected  subretinally.  The  injected
retinal area was visualized by fluorescein-positive subretinal
blebs demarking the retinal detachment. Such detachments
were usually resolved within 24 h. Signs of injection-related
damage included large holes in the cornea with accompanying
iris–cornea adhesion, hemorrhage in the iris or retina, and
damage to the lens, causing cataract formation. Animals with
any of these complications were removed from further study.
In animals with no apparent surgical complications, only those
whose retinal blebs occupying more than 90% of the retina
were retained for further evaluation. Twenty mice met this
standard in the study, which included three rd12 mice that
received  only  a  single  subretinal  injection  for  ERG
examination, three rd12 mice that received an intravitreal
injection followed by a subretinal injection in the partner eyes
for  ERG  examination,  six  rd12  mice  that  received  an
intravitreal  injection  followed  by  subretinal  injection  in
partner eyes for immunostaining, and eight C57BL/6J mice
that  received  intravitreal  injection  followed  by  subretinal
injection  in  partner  eyes  for  retinal  whole-mount  and
sectioning examinations. One drop of 1% atropine (Hi-Tech
Pharmacal Co. Inc., Amityville, NY) and a small amount of
Neomycin and Polymyxin B Sulfates and Dexamethasone
Ophthalmic Ointment (E. Fougera and Co., Melville, NY)
were applied to the eye following injection and then applied
once  daily  for  three  days  to  prevent  the  injection-related
inflammation and iris-cornea adhesion as well as bacteria and
fungi infections. Evaluation was performed five months after
the second SR injection.
Electroretinogram recording and statistical analysis: Nine
rd12 and nine C57BL/6J mice were dark adapted overnight
and anesthetized with a mixture of ketamine (15 mg/g) and
xylazine (5 mg/g bodyweight) under dim red light. The pupils
were dilated with a single drop of 1% atropine sulfate. A drop
of 0.5% proparacaine hydrochloride was applied for corneal
anesthesia. The temperature of the room was maintained at
38  °C.  A  small  amount  of  2.5%  methylcellulose  gel  was
applied to the eye. A silver loop electrode was placed over the
cornea  to  record  the  ERGs.  Needle  reference  and  ground
electrodes were inserted into the cheek and tail, respectively.
The responses were differentially amplified (1–500Hz). All
stimuli were presented in a Ganzfeld dome (Roland Q400,
Wiesbaden, Germany). Light was spectrally filtered with a
500-nm interference filter. Flashes varied in intensity from
−5.0 to 0 log scotopic candela-sec/m2. For reporting b-wave
amplitudes, data in each group (n=3) was expressed as mean
±standard deviation (SD), and the significant difference was
judged by one-way Analysis of Variance (ANOVA). Least
Significant Difference (LSD) was then used for a post hoc test.
Histology: Mouse eyes were enucleated and fixed overnight
with  4%  paraformaldehyde  in  phosphate-buffered  saline
(dPBS; Mediatech, Inc., Herndon, VA) after removal of the
cornea. Eyecups were then prepared by removing the lens.
Retinal whole-mounts were prepared by removing the choroid
and sclera from the eyecups. The whole-mounts were then
placed on a slide (photoreceptors down) and coverslipped
before photographing. Frozen sections were prepared from
eyecups,  rinsed  four  times  in  dPBS,  transferred  to  30%
sucrose  in  dPBS  for  5  h,  and  frozen  in  optimal-cutting
temperature  medium  (Fisher  Scientific,  Pittsburgh,  PA).
Twelve-micrometer  thick  sections  were  obtained  with  a
cryostat. GFP-specific fluorescence was analyzed using an
Olympus  CK40  inverted  microscope  (Olympus,  Tokyo,
Japan).  True  GFP  fluorescence  was  distinguished  from
background autofluorescence by comparing signals through a
fluorescein  isothiocyanate  (FITC)  and  a  rhodamine  filter.
Sections  expressing  GFP  were  covered  with  Vectashield
mounting medium (Vector Laboratories, Burlingame, CA)
and photographed using a Spot RT (real-time) digital camera
(Diagnostic Instruments Color Digital Cameras, McHenry,
IL).
Immunocytochemistry for RPE65: Eyes from C57BL/6J mice
and from both injected eyes of rd12 mice at seven months of
age were used to prepare frozen sections as described above.
Following permeabilization with 0.1% Triton X-100, 12-μm
thick frozen sections mounted on coated slides were rinsed
with dPBS (Mediatech, Inc., Herndon, VA), blocked with
20% normal goat serum (NGS), incubated overnight at 4 °C
in  rabbit  polyclonal  raised  anti-human/bovine  RPE65
antibodies (Abcam, Cambridge, UK), and diluted 1:400 in
NGS. After three rinses with dPBS, sections were incubated
in  goat  anti-rabbit  Texas  red  (1:300,  Molecular  Probes,
Eugene, OR) for 2 h followed by three rinses with dPBS.
Sections were then mounted with coverslips for fluorescence
photography.
RESULTS
Effect  of  vector  expression  following  intravitreal  and
subretinal  injection  of  scAAV5-smCBA-GFP  to  C57BL/6J
mice:  Retinal  whole-mount  analysis  showed  minimal
transduction in the retina mainly around the injection site six
months following the first intravitreal injection of scAAV5-
smCBA-GFP (Figure 1A). Fluorescent microscopy showed
that those GFP positive cells were mainly RPE and PR cells
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269(Figure 1B). Very few GFP positive retinal ganglion cells
(RGCs) could be detected, and the few detected were found
only  around  the  injection  site.  In  contrast,  retinal  whole-
mounts  subretinally  injected  with  the  same  AAV5  vector
showed strong GFP expression throughout the entire retina
five months following the second subretinal injection (Figure
1C). Fluorescent microscopy of transverse retinal sections
showed strong GFP expression mainly in the RPE and PR cells
after subretinal injection of scAAV5-smCBA-GFP (Figure
1D). Rd12 mice in which only one eye received subretinal
scAAV5-smCBA-GFP at eight weeks of age showed similar
results as those shown in Figure 1C,D (data not shown).
RPE65  expression  following  intravitreal  and  subretinal
injections of scAAV5-smCBA-hRPE65 vector into rd12 mice:
Stable RPE65 expression throughout the whole retina was
observed in the rd12 eyes five months after the subretinal
injection of scAAV5-smCBA-hRPE65 (Figure 2A). In the
contralateral eyes, which received an intravitreal injection
with  the  same  vector  four  weeks  before  the  subretinal
injection, little RPE65 expression could be detected (Figure
2B) except modest expression around the injection site (data
not  shown).  High  magnification  fluorescence  microscopy
(Figure 2C) showed that RPE65 was mainly located in the
RPE cells of the rd12 eye following the subretinal injection
of scAAV5-smCBA-hRPE65. In the partner rd12 eye that
received  an  intravitreal  injection,  no  obvious  RPE65
expression was detected (Figure 2D). Occasionally, a weak
signal could also be detected in the RPE and PR cells under
high magnification around the injection site (data not shown).
Electroretinographic analysis: A series of ERG responses
from  seven-month-old,  uninjected,  normal  C57BL/6J,  and
rd12 eyes are shown in Figure 3A,B, respectively. The rd12
eye, which received a subretinal injection four weeks after an
intravitreal  injection  in  the  contralateral  eye  of  the  same
Figure 1. AAV5-mediated GFP expression both in retinal whole mounts and frozen sections following intravitreal and subretinal injection of
scAAV5-smCBA-GFP.  Higher  transduction  efficiency  is  seen  following  subretinal  injection  compared  to  intravitreal  injection.  A:
Fluorescence image of a retinal whole-mount six months following intravitreal injection. B: Fluorescence image of a frozen section six months
following intravitreal injection. C: Fluorescence image of a retinal whole-mount five months after subretinal injection (the partner eye of this
mouse was pretreated with the same vector by intravitreal injection one month earlier). D: Fluorescence image of a frozen section as in (C).
Abbreviations: RPE represents retinal pigment epithelium; IS represents inner segments of photoreceptor cell; ONL represents outer nuclear
layer; INL represents inner nuclear layer; GCL represents ganglion cell layer.
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270mouse  (Figure  3C),  showed  robust,  dark-adapted  ERG
restoration  five  months  after  the  subretinal  injection.  The
amplitude was similar to the rd12 eye that received only one
subretinal injection at a similar age (Figure 3D). In contrast,
the intravitreally injected rd12 eye (Figure 3E, contralateral
eye of Figure 3C) showed little or no dark-adapted ERG
signal, similar to the age-matched uninjected rd12 eye (Figure
3B).  The  b-wave  amplitudes  (Figure  4)  from  each
experimental group are 536.7±41.1 μV (maximum response)
in normal, seven-month-old C57BL/6J eyes, 293.7±26.8 μV
(maximum response) in rd12 eyes five months following a
subretinal injection at eight weeks old (four weeks following
intravitreal  injection  in  the  partner  eye),  317.3±42.2  μV
(maximum response) in rd12 eyes five months following a
single subretinal injection at eight weeks old, 16.7±28.9 μV
(maximum  response)  in  seven-month-old,  untreated  rd12
eyes, and 15.0±9.0 μV (maximum response) in rd12 eyes six
months following intravitreal injection at four weeks old. The
maximum  b-wave  amplitudes  (Figure  4)  in  subretinally
treated rd12 eyes were about 55% of those in the normal,
uninjected  C57BL/6J  eyes.  Statistical  analysis  (Figure  4)
showed that rd12 eyes that received either a second subretinal
injection (n=3, p<0.001) or a single subretinal injection (n=3,
p=0.001) had significantly higher b-wave amplitudes than the
untreated rd12 eyes. However, treated rd12 eyes had lower b-
wave amplitudes than those in the normal, uninjected C57BL/
6J eyes (n=3, p<0.001). Although the average amplitude of b-
waves in eyes receiving the second subretinal injection were
slightly  lower  than  in  eyes  receiving  a  single  subretinal
injection,  there  was  no  statistically  significant  difference
between these two groups (n=3, p=0.458). Also, there was no
statistical difference in b-wave amplitudes from seven-month-
old rd12 eyes either receiving intravitreal injection at four
weeks old (n=3) or receiving no injection (n=3, p=0.944).
DISCUSSION
AAV  vectors  have  many  attractive  features  for  safe  and
efficient gene therapy including their lack of pathogenesis,
low toxicity, ability to efficiently infect both dividing and non-
dividing cells in broad range of host tissues/organs, and long-
term gene expression [35,36]. The ability of AAV vectors to
efficiently  transduce  retinal  cells  has  been  exploited  to
successfully transfer therapeutic genes into PR, RPE, and
RGCs  [37],  to  treat  a  variety  of  retinal  diseases  causing
Figure 2. RPE65 immunoreactivity after
intravitreal and subretinal injections of
scAAV5-smCBA-hRPE65  vector.
Little RPE65 expression was detected in
an  rd12  eye  six  months  after  the
intravitreal  injection  (B),  which  was
further  supported  by  a  higher
magnification  image  (D).  RPE65
expression was detected in the RPE cells
of the contralateral eye from the same
rd12 mouse five months after subretinal
injection  (A),  which  was  further
supported  by  a  higher  magnification
image  (C).  Abbreviations:  RPE
represents  retinal  pigment  epithelium;
OS  represents  outer  segments  of
photoreceptor cell; IS represents inner
segments  of  photoreceptor  cell;  ONL
represents  outer  nuclear  layer;  INL
represents  inner  nuclear  layer;  GCL
represents  retinal  ganglion  cell  layer.
The asterisk shows retinal detachment.
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271blindness in animal models [26,38,39] and now in human
LCA [21–24].
A key consideration in the design of the delivery vector
for gene therapy is the AAV serotype. Adeno-associated virus
type 5 (AAV5) is one of the most divergent of the AAV
serotypes, sharing only 64% overall nucleotide identity with
the prototype AAV2 [40,41]. While the basic transcription
profile of AAV5 is similar to that of AAV2, there are also
significant differences [42]. In contrast to AAV2 that can
efficiently transduce the ganglion cells following intravitreal
injection,  AAV5  vectors  only  transduce  retinal  cells
inefficiently following intravitreal injection [37]. It is difficult
to  compare  ERG  restoration  differences  in  the  two  rd12
groups even when both received subretinal injections because
the retinal transduction areas vary unpredictably with each
subretinal injection. Therefore, we only used mice that had no
injection related complications and had at least 90% of the
retina detached upon subretinal injection.
In parallel experiments, we found that rd12 eyes showed
similar rod-related ERG restoration following either an initial
subretinal injection of scAAV2-smCBA-RPE65 or a second
subretinal  injection  when  the  other  eye  had  received  an
intravitreal injection of the same vector four weeks before.
However,  we  also  noted  that  a  subretinal  injection  of
scAAV5-smCBA-RPE65 led to better ERG restoration than
scAAV2-smCBA-RPE65  and  that  scAAV5-smCBA-
hRPE65 was slightly better than the corresponding vector
containing  a  0.9  kb  larger  CBA  promoter,  AAV5-CBA-
hRPE65 (data not shown). Thus, serotype 5 scAAV-smCBA-
RPE65 was chosen as the delivery vector over serotype 2
Figure  3.  Dark-adapted  (rod-derived)
ERG analysis showing retinal function
of  seven-month-old  normal  and  rd12
mice  following  either  intravitreal  or
subretinal  injection,  or  no  injection.
Restored  ERGs  are  independent  of
whether the partner eye was pretreated
with  the  same  vector  or  not.  Dark-
adapted  photoresponses  are  shown  at
different input flash intensities from an
uninjected normal C57BL/6 (A) and an
uninjected rd12 eye (B). Panel C shows
the ERGs from the left eye of an rd12
mouse  five  months  after  subretinal
injection at eight weeks of age, while the
right  eye  of  the  same  mouse  had
received intravitreal vector four weeks
before the subretinal injection (E). Panel
D shows ERGs from an rd12 eye five
months  following  only  a  subretinal
injection at eight weeks of age with no
prior treatment of the partner eye.
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272because it can transfect more RPE and PR cells [26,37,43,
44] and yield more RPE65 protein at the desired site.
Immunohistochemical data reported here suggest that the
AAV5-mediated  delivery  of  human  RPE65  results  in
sustained human RPE65 protein expression in the rd12 retina
for  at  least  five  months  that  correlates  with  a  sustained
restoration of dark-adapted ERG signals. RPE65 expression
and ERG restoration has been detected as early as four weeks
following subretinal injection (data not shown) and remained
stable for at least five months after subretinal injection, the
longest time we observed in this study. This biochemical and
functional restoration was independent of whether the partner
eye was pretreated or not with the same vector and suggests
that AAV-mediated RPE65 expression and therapy following
subretinal injection is not modified by previous intravitreal
injection in the partner eye.
It is known that following intravitreal injection of AAV
vector, a systemic antibody will form that can then alter the
transduction efficacy of inner retinal cells in the partner eye
upon a subsequent intravitreal vector injection [10]. In that
study, a strong humoral immune response against AAV capsid
was  observed  four  weeks  after  intravitreal  treatment  with
AAV5-RPE65 vector. This was the main reason for choosing
this  specific  timing  between  contralateral  intravitreal  and
subretinal injections. Therefore, our principal finding was
therapeutic.  AAV-mediated  RPE65  expression  and  ERG
functional rescue were not reduced if the subretinal injection
was preceded by an intravitreal injection of the same vector
into the contralateral eye. Indeed, there is no reduction of the
therapeutic effect (as determined by ERG amplitudes in the
subretinally injected eye) no matter whether the partner eye
was pretreated with the same vector or not. This suggests that,
as far as RPE targeted therapy is concerned, the subretinal
space possesses full immune privilege.
Our results are consistent with those of Bennett et al.
[45] and Anand et al. [46] in which non-human primate and
murine  RPE  and  PR  cells  were  shown  to  be  transduced
efficiently by subretinal injection of AAV vectors in spite of
the  presence  of  circulating  antibodies  to  AAV  capsid.
Furthermore, our findings have added clinical implications for
the design of gene therapy protocols aimed either at targeting
different retinal cell types in different ocular compartments of
the same eye or at treating partner eyes sequentially. Although
care must be taken in extrapolating results in mice to humans,
particularly under pathological conditions, our results suggest
that it is safe to re-administer AAV vectors into the subretinal
space to target PR and RPE cells without compromising the
efficacy of the repeated gene transfers.
Figure  4.  ERG  signals  following
different injections. Dark-adapted ERG
b-wave  amplitudes  under  different
intensities  show  dramatic  ERG
restoration  in  rd12  mice  5  months
following  subretinal  injection.
Statistical  analysis  demonstrates  that
functional  restoration  following
subretinal  injection  is  independent  of
whether the partner eye was pretreated
with the same vector or not. Each of the
five groups had three mice. The yellow
curve represents the uninjected, normal
C57BL/6J eyes at seven months of age.
The blue curve represents the rd12 eyes
at  seven  months  of  age  following  an
initial subretinal injection of scAAV5-
smCBA-hRPE65 when they were eight
weeks old. The brown curve represents
the right eyes of rd12 mice six months
following the intravitreal injection that
occurred  when  they  were  four  weeks
old. The green curve represents the left
eyes of rd12 mice five months following
the  subretinal  injection  they  received
when they were eight weeks old (the
right eyes of these mice received the
intravitreal  vector  four  weeks  before
their  subretinal  injections).  The  pink
curve represents the untreated rd12 eyes
at seven months of age. Bars: mean±SD.
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